Moreover, melanoma patients who express low levels of CXCL9 or CXCL10 (either blood or tumor site) are poor responders to ICT, and those with high levels of CXCL9 or CXCL10 respond more favorably (18, 19). The gene discussed is CXCL10; the disease is melanoma.